Heterogeneity of EpCAM-positive cells in low-grade serous ovarian carcinoma ascitic fluid: a clinical case
https://doi.org/10.17650/1994-4098-2021-17-4-90-95
Abstract
Ovarian cancer is one of the most malignant and aggressive tumors of the female reproductive system. Late diagnosis is one of the most significant problems: more than two-thirds of cases are detected only at stage III–IV. Ovarian cancer is characterized by a unique metastatic process. Implantation is the earliest and most common way of metastasis. It is often accompanied by fluid accumulation in the abdominal cavity, known as ascites. We report a case of low-grade serous ovarian carcinoma with a large heterogeneity of tumor cells in the ascitic fluid detected using multicolor flow cytometry. We demonstrated the advantages and benefits of this method in the diagnosis of ovarian cancer. Multicolor flow cytometry opens new horizons for liquid biopsy in oncology.
Keywords
low-grade ovarian serous carcinoma,
ascitic tumor cells,
tumor heterogeneity,
EpCAM,
multicolor flow cytometry,
liquid biopsy
Supporting agencies: This work was funded by grant of the President of the Russian Federation MD-2017.2020.7. The authors are grateful to The Core Facility “Medical genomics”, Tomsk National Research Medical Center of the Russian Academy of Sciences for the opportunity to use scientific equipment.
About the Authors
E. V. Kaigorodova
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences; Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
Evgeniya Viktorovna Kaigorodova.
5, Kooperativnyy St., Tomsk 634009; 2, Mosсovskiy Trakt, Tomsk 634050.
Competing Interests:
The authors declare no conflict of interest.
O. V. Kovalev
Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
2, Mosсovskiy Trakt, Tomsk 634050.
Competing Interests:
The authors declare no conflict of interest.
A. L. Chernyshova
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativnyy St., Tomsk 634009.
Competing Interests:
The authors declare no conflict of interest.
S. V. Vtorushin
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences; Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativnyy St., Tomsk 634009; 2, Mosсovskiy Trakt, Tomsk 634050.
Competing Interests:
The authors declare no conflict of interest.
O. V. Shpileva
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativnyy St., Tomsk 634009.
Competing Interests:
The authors declare no conflict of interest.
References
1. Malignant tumors in Russia in 2018 (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 2019. 250 p. (In Russ.).
2. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359–86. DOI: 10.1002/ijc.29210.
3. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68(1):7–30. DOI: 10.3322/caac.21442.
4. Lheureux S., Braunstein M., Oza A.M. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019;69(4):280–304. DOI: 10.3322/caac.21559.
5. Matulonis U.A., Sood A.K., Fallowfield L. et al. Ovarian cancer. Nat Rev Dis Primers 2016;2:16061. DOI: 10.1038/nrdp.2016.61.
6. Reid F., Bhatla N., Oza A.M. et al. The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life. Int J Gynecol Cancer 2021;31(2):238–44. DOI: 10.1136/ijgc-2019-000983.
7. Kaldawy A., Segev Y., Lavie O. et al, Lowgrade serous ovarian cancer: A review. Gynecol Oncol 2016;143(2):433–8. DOI: 10.1016/j.ygyno.2016.08.320.
8. Kaigorodova E.V., Fedulova N.V., Ochirov M.O. et al. Dissimilar tumor cell populations in ascitic fluid of ovarian cancer patients. Bulletin of Siberian Medicine 2020;19(1):50–8. DOI: 10.20538/1682-0363-2020-1-50-58.
9. Hatina J., Boesch M., Sopper S. et al. Ovarian Cancer Stem Cell Heterogeneity. Adv Exp Med Biol 2019;1139:201–21. DOI: 10.1007/978-3-030-14366-4_12.
10. Keller L., Werner S., Pantel K. Biology and clinical relevance of EpCAM. Cell Stress 2019;3(6):165–80. DOI: 10.15698/cst2019.06.188.
11. Tavsan Z., Ayar Kayalı H. EpCAMclaudin-tetraspanin-modulated ovarian cancer progression and drug resistance. Cell Adh Migr 202;14(1):57–68. DOI: 10.1080/19336918.2020.1732761.
12. Kaigorodova E.V., Ochirov M.O., Molchanov S.V. et al. Dissimilar populations of EpСam-positive cells in ascitic fluid of ovarian cancer patients: a relationship with the degree of carcinomatosis. Bulletin of Siberian Medicine 2021;20(2):44–53. DOI: 10.20538/1682-0363-2021-2-44-53.
Review
For citations:
Kaigorodova E.V., Kovalev O.V., Chernyshova A.L., Vtorushin S.V., Shpileva .V. Heterogeneity of EpCAM-positive cells in low-grade serous ovarian carcinoma ascitic fluid: a clinical case. Tumors of female reproductive system. 2021;17(4):90-95. (In Russ.) https://doi.org/10.17650/1994-4098-2021-17-4-90-95
Views:
491
Email this article 